Abstract
To review the role of radiation therapy and specifically metastasis-directed stereotactic body radiation therapy (SBRT) in the management of patients with oligometastatic breast cancer with emphasis on potential toxicities and future directions. Recent prospective studies have demonstrated encouraging initial results indicating the potential efficacy of metastasis-directed SBRT in the management of patients with oligometastatic disease. However, given potentially significant toxicities associated with metastasis-directed SBRT, additional data in the form of phase III randomized control trials are needed to define the role of SBRT in the management of patients with oligometastatic breast cancer; such studies are currently ongoing. While current data are encouraging, additional data are required to determine the benefit of SBRT in patients with oligometastatic breast cancer. Physicians opting to treat patients with metastasis-directed SBRT should ideally do so on protocol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
